Online inquiry

IVTScrip™ mRNA-Anti-CD3E&IL3RA, XmAb14045(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15816MR)

This product GTTS-WQ15816MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD3E&IL3RA gene. The antibody can be applied in Acute lymphocytic leukemia (ALL) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_000733.4; NM_001267713.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 3563
UniProt ID P07766; P26951
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&IL3RA, XmAb14045(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ15816MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9349MR IVTScrip™ mRNA-Anti-PDCD1, INCMGA-00012(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA INCMGA-00012
GTTS-WQ4581MR IVTScrip™ mRNA-Anti-CD40LG, BMS-986004(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BMS-986004
GTTS-WQ12604MR IVTScrip™ mRNA-Anti-F11, NVS250519(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA NVS250519
GTTS-WQ6957MR IVTScrip™ mRNA-Anti-VEGFA, ESBA-1008(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ESBA-1008
GTTS-WQ5734MR IVTScrip™ mRNA-Anti-CEACAM5, CEA-IL-2v(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CEA-IL-2v
GTTS-WQ2139MR IVTScrip™ mRNA-Anti-CGRP, ALD-403(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ALD-403
GTTS-WQ15042MR IVTScrip™ mRNA-Anti-CD47, SRF-231(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SRF-231
GTTS-WQ5509MR IVTScrip™ mRNA-Anti-IL17A&IL17F, CDP4940(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CDP4940
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW